Holen Sie sich die Stockscreener-App
38.32
1.31%
-0.52
Schlusskurs vom Vortag:
$38.84
Offen:
$39.19
24-Stunden-Volumen:
158.06K
Relative Volume:
0.15
Marktkapitalisierung:
$3.70B
Einnahmen:
$225.27M
Nettoeinkommen (Verlust:
$-140.06M
KGV:
-23.99
EPS:
-1.5974
Netto-Cashflow:
$-87.93M
1W Leistung:
-4.58%
1M Leistung:
+3.54%
6M Leistung:
+9.26%
1J Leistung:
+54.93%
1-Tages-Spanne:
$38.21
$39.19
1-Wochen-Bereich:
$38.21
$40.66
52-Wochen-Spanne:
$24.24
$42.68
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Firmenname
Ideaya Biosciences Inc
Sektor
Branche
Telefon
650-443-6209
Adresse
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
38.37 | 3.75B | 225.27M | -140.06M | -87.93M | -1.5974 |
VRTX
Vertex Pharmaceuticals Inc
|
520.43 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
802.59 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.56 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.13 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.47 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-09-18 | Eingeleitet | Guggenheim | Buy |
| 2025-09-04 | Eingeleitet | Barclays | Overweight |
| 2025-09-04 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-07-22 | Eingeleitet | TD Cowen | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-26 | Eingeleitet | Wells Fargo | Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-11-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2024-03-08 | Eingeleitet | BTIG Research | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Outperform |
| 2023-05-24 | Eingeleitet | Goldman | Buy |
| 2023-04-24 | Hochstufung | Stifel | Hold → Buy |
| 2023-03-23 | Eingeleitet | Berenberg | Buy |
| 2023-02-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-28 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-27 | Eingeleitet | Citigroup | Buy |
| 2022-08-15 | Herabstufung | Stifel | Buy → Hold |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-10 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-11 | Eingeleitet | Guggenheim | Buy |
| 2020-10-07 | Eingeleitet | Wedbush | Outperform |
| 2020-09-01 | Eingeleitet | Northland Capital | Outperform |
| 2020-07-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-17 | Eingeleitet | Oppenheimer | Outperform |
| 2019-09-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-17 | Eingeleitet | Citigroup | Buy |
| 2019-06-17 | Eingeleitet | JP Morgan | Neutral |
| 2019-06-17 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
IDEAYA Biosciences Doses First Patient in Phase 3 Trial - grafa.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data - Investing.com
Guggenheim raises Ideaya Biosciences stock price target on DLL3 data By Investing.com - Investing.com Canada
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma - PR Newswire
IDEAYA at wells fargo healthcare conference: darovasertib nears NDA By Investing.com - Investing.com Canada
Phase III path opens for Ideaya’s IDE-849 in DLL3 ADC horse race - BioWorld News
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress By Investing.com - Investing.com Nigeria
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences - PR Newswire
Citizens upgrades Ideaya Biosciences stock rating on IDE849 progress - Investing.com
IDEAYA Biosciences Sets London R&D Day for Nov. 16 | IDYA Stock News - Stock Titan
Avoiding Lag: Real-Time Signals in (IDYA) Movement - Stock Traders Daily
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer - PR Newswire
IDEAYA Biosciences (IDYA) Slips 2.3% to $40.81 as Biotech Momentum FadesMomentum Factor - vinanet.vn
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Ideaya Biosciences stock hits 52-week high at 40.88 USD By Investing.com - Investing.com Nigeria
Ideaya Biosciences stock hits 52-week high at 40.88 USD - Investing.com
Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform (IDYA) - Seeking Alpha
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Eastern Progress
Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA (IDYA) Results Check: The EPS Result Is Below Expectation in Latest Trading; Shares Close 2.48% Higher for the Current SessionEarnings Miss Alert - Vinanet
symbol__ Stock Quote Price and Forecast - CNN
IDEAYA partners with Genentech on pancreatic cancer trial By Investing.com - Investing.com South Africa
IDEAYA partners with Genentech on pancreatic cancer trial - Investing.com
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer - PR Newswire
Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences (IDYA) Cash Flow Statement - Moomoo
Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Baker Bros. Advisors (IDYA) reports 5.2% IDEAYA stake and capped warrants - Stock Titan
IDEAYA Biosciences (IDYA) Holds Near $37 as Bulls Eye Breakout Above $38.81 ResistanceVolume Breakout Ideas - Vinanet
J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $62 - Moomoo
IDEAYA Biosciences (IDYA) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
How (IDYA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
IDEAYA Biosciences (NASDAQ:IDYA) Displays Perfect Technical Strength and Breakout Setup - ChartMill
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58 - Moomoo
IDEAYA Biosciences Inc (IDYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
IDEAYA Biosciences (NASDAQ:IDYA) Is In A Strong Position To Grow Its Business - Moomoo
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48 - Moomoo
The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership - Yahoo Finance
IDEAYA Biosciences (NASDAQ:IDYA) Given New $59.00 Price Target at Truist Financial - MarketBeat
Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $59 - Moomoo
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $48 to $60 - Moomoo
IDEAYA BIOSCIENCES, INC. : LEERINK PARTNERS CUTS TARGET PRICE TO $31 FROM $37 - Bitget
IDEAYA Biosciences 2Q 2026: Revenue $8.86M, EPS $(1.22) — 10-Q Summary - TradingView
IDEAYA Biosciences (NASDAQ: IDYA) reports $1.24B cash and rising R&D spend - stocktitan.net
IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS - MarketBeat
IDEAYA Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (IDYA) IDEAYA Biosciences, Inc. Reports Q2 Revenue $8.9M, vs. FactSet Est of $8.0M - marketscreener.com
Finanzdaten der Ideaya Biosciences Inc-Aktie (IDYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ideaya Biosciences Inc-Aktie (IDYA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ruiz Briseno Andres | Chief Accounting Officer |
Jul 07 '26 |
Sale |
40.01 |
9,550 |
382,131 |
26,466 |
0.83%
2.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):